文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

头孢吡肟诱导的神经毒性:临床、脑电图特征及预后因素的回顾性研究

Clinical, Electroencephalographic Features and Prognostic Factors of Cefepime-Induced Neurotoxicity: A Retrospective Study.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论头孢吡肟神经毒性患者住院死亡率达40%,维持性血液透析和较长用药疗程独立相关,早期识别脑电图异常并停药可改善预后。

该回顾性研究分析了2007至2016年台湾某三级医疗中心42例头孢吡肟治疗后出现脑病的患者(平均年龄75.8±11.8岁,50%慢性肾病,43%急性肾损伤,76%已调整剂量),其中64%出现非惊厥性癫痫持续状态,40%未存活至出院。Logistic回归显示维持性血液透析(OR 3.8)和较长头孢吡肟疗程(OR 1.2)与神经毒性发生独立相关。适当调整剂量和早期停药与更好预后相关,提示早期识别脑电图异常并及时停药对改善结局至关重要。

要点

  • 头孢吡肟神经毒性患者中非惊厥性癫痫持续状态发生率达64%,40%未存活至出院。
  • 维持性血液透析(OR 3.8)和较长头孢吡肟疗程(OR 1.2)与神经毒性发生独立相关。
  • 76%患者已适当调整头孢吡肟剂量,3例肾功能正常者仍发生神经毒性。
  • 适当调整剂量和早期停用头孢吡肟可带来更好预后。
  • 广泛周期性放电伴或不伴三相波形态是最常见脑电图模式(38%)。

适用人群与场景

  • 2007至2016年在台湾某三级医疗中心接受脑电图检查、头孢吡肟治疗后出现脑病的患者,包括病房25例和ICU 17例。

处置流程与药物剂量

  • 适当调整头孢吡肟剂量和早期停用头孢吡肟可带来更好预后。
  • 86%的患者接受了抗癫痫药物治疗。

红旗征与不能漏的情况

  • 非惊厥性癫痫持续状态在头孢吡肟神经毒性患者中频繁出现(64%)。
  • 广泛周期性放电伴或不伴三相波形态是最常见脑电图模式(38%),其次为广泛节律性δ活动和广泛棘慢波。

研究设计与关键结果

  • 回顾性研究共纳入42例头孢吡肟神经毒性患者,平均年龄75.8±11.8岁,21例(50%)有慢性肾病,18例(43%)有急性肾损伤,32例(76%)接受了适当的头孢吡肟剂量调整,3例在神经毒性发生时肾功能正常。
  • Logistic回归模型提示维持性血液透析和较长头孢吡肟使用疗程与神经毒性发生独立相关,比值比分别为3.8和1.2。
  • 非惊厥性癫痫持续状态在头孢吡肟神经毒性患者中频繁出现(64%);广泛周期性放电伴或不伴三相波形态是最常见脑电图模式(38%),其次为广泛节律性δ活动和广泛棘慢波。
  • 86%的患者接受了抗癫痫药物治疗;17例(40%)未存活至出院。
  • 适当调整头孢吡肟剂量和早期停用头孢吡肟带来更好预后。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于接受头孢吡肟治疗的患者,即使已调整剂量或肾功能正常,仍可能出现神经毒性症状,需警惕脑病表现。
  • 维持性血液透析或较长头孢吡肟疗程的患者更易发生神经毒性,应加强监测。
  • 早期识别脑电图异常并停用头孢吡肟可带来临床改善和更好的出院预后。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The incidence of cefepime-induced neurotoxicity (CIN) has been previously underestimated, and there have only been sporadic reports from critical neurological settings. The present study aimed to investigate the potential factors associated with disease development, electroencephalography (EEG) sub-classification, and outcome measures.

METHODS: The 10-year medical records of patients who underwent EEG between 2007 and 2016 at a tertiary medical center in Taiwan, and developed encephalopathy after cefepime therapy were retrospectively reviewed. Age- and sex-matched controls were included for further analysis. Demographic data, the occurrence of clinical seizures, non-convulsive status epilepticus (NCSE), use of antiepileptic drugs (AEDs), receiving maintenance or urgent hemodialysis, EEG findings, and functional outcomes were analyzed. The Chi-square test and a logistic regression model were applied to survey significant prognostic factors relating to mortality.

RESULTS: A total of 42 CIN patients were identified, including 25 patients from wards and 17 from intensive care units; their mean age was 75.8 ± 11.8 years. Twenty-one patients (50%) had chronic kidney disease, and 18 (43%) had acute kidney injury. Among these patients, 32 (76%) received appropriate cefepime dose adjustment. Three patients had a normal renal function at the time of CIN onset. The logistic regression model suggested that maintenance hemodialysis and longer duration of cefepime use were independently associated with the development of CIN, with odds ratios of 3.8 and 1.2, respectively. NCSE was frequently noted in the CIN patients (64%). Generalized periodic discharge with or without triphasic morphology was the most common EEG pattern (38%), followed by generalized rhythmic delta activity and generalized spike-and-waves. AEDs were administered to 86% of the patients. A total of 17 patients (40%) did not survive to hospital discharge. Adequate cefepime dose adjustment and early cefepime discontinuation led to a better prognosis.

CONCLUSIONS: CIN was associated with high mortality and morbidity rates. Neurotoxic symptoms could still occur when the cefepime dose was adjusted, or in patients with normal renal function. Patients with maintenance hemodialysis or a longer duration of cefepime therapy tended to develop CIN. Early recognition of abnormal EEG findings allowed for the withdrawal of the offending agent, resulting in clinical improvements and a better prognosis at discharge.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Li HT, Lee CH, Wu T, et al. Clinical, Electroencephalographic Features and Prognostic Factors of Cefepime-Induced Neurotoxicity: A Retrospective Study. Neurocrit Care. 2019. PMID: 30756319. doi:10.1007/s12028-019-00682-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。